The warning was public three years before the deal closed. So was the science disputing it. What Bayer could not see was the size of the liability that fight would become.
"Probably carcinogenic to humans." That is how the World Health Organization's cancer research agency described glyphosate, the active ingredient in the weed killer Roundup, in March 2015. The United States Environmental Protection Agency studied the same chemical and reached the opposite conclusion, that glyphosate is "not likely to be carcinogenic to humans." Both findings sat in the public record. In 2018, Bayer paid sixty-three billion dollars for the company that made Roundup.
Sixty-four days after the deal closed, a jury in San Francisco returned the first Roundup cancer verdict, two hundred eighty-nine million dollars, to a dying school groundskeeper named Dewayne Johnson. Courts later reduced his award to about twenty million dollars on appeal. The market did not wait for the appeal. The next trading day, Bayer's stock fell more than ten percent in a single session, on a verdict handed down in a courtroom three thousand miles from its headquarters.
The two findings that framed the entire fight were available before Bayer wired the money. What no one had reduced to a single number was the size of the liability a public scientific dispute like that would generate in front of juries, year after year. Bayer priced the company as a chemistry and seed business. The market repriced it as a litigation business the morning after the first verdict. By June 2020, Bayer had announced settlement agreements worth up to 10.9 billion dollars to resolve about three quarters of the Roundup litigation then pending, out of roughly 125,000 filed and unfiled claims.
If you sit at the top of a legal department or a claims organization, you are managing somewhere between a few hundred and a few thousand open matters right now. You have a system of record. It holds your files, your documents, your spend. When the board asks why outcomes are not improving, the reflex is to assume the system is the problem and go shopping for a new one. That reflex is the expensive one, and it is usually aimed at the wrong target.
The system is not why your outcomes are flat. The reason is what no one ever asked the system to tell you. Thomson Reuters' 2025 Legal Department Operations Index found that the service-centric measures, the quality of legal outcomes, cycle time, and cost avoided, are tracked by fewer than one in five legal departments. Almost everyone tracks spend. Almost no one tracks whether the spend bought a good result. You are watching the meter. You are not watching the road.
That is what managing claims looks like. You track what each matter costs. You read narratives from outside counsel that arrive a quarter after the decisions they describe were already made. You have no way to say whether the firm on your highest-exposure matter wins this kind of case, in this venue, against this opponent, more often than the firm you passed over. You walk into mediation with no read on where the case is actually heading. None of that is a record-keeping failure. It is a seeing failure. And it does not register as a problem until it registers as a verdict.
When it registers, it does not show up small anymore. In 2024 there were 135 corporate verdicts of ten million dollars or more in the United States, totaling 31.3 billion dollars. The dollar value of those verdicts more than doubled in a single year. These are the numbers that turn one unwatched matter into a board-level event.
Roundup itself never stopped generating them. In January 2024, almost six years after the Johnson verdict, a Philadelphia jury awarded a single plaintiff 2.25 billion dollars in a Roundup case. A trial court later cut that award to 400 million dollars, and the matter is on appeal. Read the first number again. One plaintiff. One product. Years after Bayer had announced settlements meant to resolve most of this.
It is not a chemical-company problem either. In February 2025, a federal jury in Georgia returned 2.5 billion dollars in punitive damages against Ford over a single pickup-truck roof collapse. Ford is appealing and calls the award extreme. The pattern under all of these is the same. A liability that was visible, in some form, long before the verdict. Priced clearly by the people on the other side of it, and not yet reduced to a single defensible number by the people who would have to pay.
Bayer priced it as a chemistry business. The market repriced it as a litigation business overnight.
Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.
Litigation intelligence is not a new system you migrate to. It is the ability to see your exposure the way the market eventually will, before the market does it for you. Real visibility across the whole portfolio instead of a quarterly snapshot. Counsel performance calibrated by venue, by case difficulty, by opposing counsel, instead of a spend report. The trajectory of a matter's severity before you sit down at mediation, instead of after. None of that requires you to tear out the system you already run. It is a layer that reads what you already keep and turns it into something you can act on.
Most organizations are not one decision away from this. They are a few stages away, and the stages do not skip. Here is the ladder, and the specific thing that breaks if you try to jump it.
Stage one is Recordkeeping. You have a system that holds your matters and your spend. Almost everyone is here. Nothing is wrong with it, except that it answers what a matter cost and nothing harder. Move past it without cleaning up the data first, and every later stage inherits numbers you cannot trust.
Stage two is Visibility. Your open portfolio becomes a live picture instead of a quarterly report. Aging matters, budget exceptions, and cases heading for trial surface on their own instead of in a status call. This requires mapping what your systems already capture and agreeing on the few fields that actually matter. Skip it and you will still learn about the runaway matter a quarter late, which is the exact failure that costs the most.
Stage three is Calibration. You build a record of how cases like yours actually resolve, by venue, by opponent, by the lawyer who handled them. This requires your closed-case history, not just your open files. Skip it and you keep assigning your highest-exposure matter on reputation and relationship, with no way to know whether the firm you trust wins this kind of case where it is being tried.
Stage four is Exposure. You can state, as a number you would defend to a board, what a matter or a portfolio could actually cost, and watch that number move before mediation rather than after. This is the kind of view the Bayer and Monsanto timeline puts on display. It requires the first three. There is no shortcut to it, because it is built out of them.
You can place yourself on that ladder in about thirty seconds. Pick your single highest-exposure matter right now. Can you say, today, whether the lawyer handling it wins this kind of case, in this venue, against this opponent, more often than the lawyer you did not assign? Can you say where its severity is heading before you reach mediation? Can you watch it move without asking anyone? If the honest answer is no, you are not at stage four. You are managing that matter. You are not seeing it.
So here is the question worth sitting with. If your highest-exposure matter went to mediation next month, could you put a number on what it could cost you, and defend that number today, without waiting on a quarterly report or a call with outside counsel? Not how much you have spent on it. What it could cost. If you cannot, the exposure is already there. You just cannot see it yet.
There is a working version of what seeing it looks like. You can walk through a live litigation portfolio the way the intelligence layer would show it to you, with the exception flags, the counsel calibration, and the exposure view in one place. It takes a few minutes. It is the difference between reading the meter and watching the road.
The findings that would define this fight were public three years before the deal closed. The market read them as money the morning after the first verdict, sixty-four days in. The exposure was there the whole time. The only question was who would see it first. See it first.
Trial drama, nuclear verdicts, and the plaintiff-firm tactics behind them. Court-reporter prose, no consultant filler. Read by litigation leaders at F500 legal departments and national carriers. Free.